Effects of γ-aminobutyric acid supplementation on glucose control in adults with prediabetes: A double-blind, randomized, placebo-controlled trial

• Published in: The American journal of clinical nutrition 2023-09, Vol.118 (3), p.708-719
• Main Authors: de Bie, Tessa H., Witkamp, Renger F., Balvers, Michiel GJ, Jongsma, Maarten A.
• Format: Article
• Language: English
• Subjects: Animal models; Blood circulation; Blood pressure; Body mass; Body mass index; Body size; Cholesterol; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diet; Dietary intake; Dietary supplements; Double-blind studies; Fasting; Fermented food; GABA; Glucagon; Glucose; Glucose monitoring; Glucose tolerance; Hemoglobin; Homeostasis; Insulin; metabolic health; overweight; Placebos; Population studies; prediabetes; sleep; Tomatoes; Triglycerides; γ-Aminobutyric acid
• ISSN: 0002-9165; 1938-3207
• DOI: 10.1016/j.ajcnut.2023.07.017

Gamma-aminobutyric acid (GABA) is mainly known as an endogenously produced neurotransmitter. However, GABA intake from dietary sources like tomatoes and fermented foods can be considerable. Studies in rodent models have shown beneficial effects of oral GABA supplementation on glucose homeostasis and cardiovascular health. Still, it is currently unknown whether oral GABA supplementation produces cardiometabolic benefits in humans. This study aimed to investigate whether oral GABA supplementation can improve glucose homeostasis in individuals at risk of developing type 2 diabetes. In a randomized, placebo-controlled, double-blind, parallel-arm trial, 52 individuals with prediabetes (classified by impaired glucose tolerance and/or impaired fasting glucose), aged 50 to 70 y with a body mass index ≥25 kg/m2 received either 500 mg GABA 3 times daily or a placebo for 95 days. The primary outcome was the effect of the intervention on glucose response after an OGTT. As exploratory secondary outcomes, markers of glycemic control (glycated hemoglobin, insulin, glucagon, mean amplitude of glycemic excursions, and standard deviation as measured with flash glucose monitoring), cardiovascular health (blood pressure, 24-h blood pressure, circulating triglycerides, cholesterol), and self-reported sleep quality were measured before and after the intervention. Compared with placebo, GABA supplementation for 95 days did not change the postprandial glucose response (0.21 mmol/L; 95% confidence interval: −0.252, 0.674; P = 0.364). After correction for the false discovery rate, all other outcomes (including fasting plasma GABA concentration) showed no significant effects from GABA intervention at a group level. GABA supplementation does not change the postprandial glucose response in individuals at risk of developing type 2 diabetes. However, based on findings in secondary outcome measures, further research is warranted in other study populations. Research could focus on the effects of GABA in individuals with advanced diabetes or other cardiometabolic disorders. This trial was registered at www.clinicaltrials.gov as NCT04303468.